Literature DB >> 30877410

1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia.

Giulia Daniele1, Alberto L'Abbate1, Antonella Turchiano1, Orazio Palumbo2, Massimo Carella2, Crocifissa Lo Cunsolo3, Paolo Iuzzolino3, Angelo Lonoce1, María Hernández-Sánchez4, Carla Minoia5, Patrizia Leone6, Jesus Maria Hernandez-Rivas4, Clelia Tiziana Storlazzi7.   

Abstract

The identification of chromosome 1 translocations and deletions is a rare and poorly investigated event in chronic lymphocytic leukemia (CLL). Nevertheless, the identification of novel additional molecular alterations is of great interest, opening to new prognostic and therapeutic strategies for such heterogeneous hematological disease. We here describe a patient affected by CLL with a mutated IGHV status, showing a balanced t(1;3)(q23.1;q21.3) translocation and a der(18)t(1;18)(q24.2;p11.32), accompanying the recurrent 13q14 heterozygous deletion in all analyzed cells at onset. By combining whole-genome sequencing, SNP array, RNA sequencing, and FISH analyses, we defined a 1q23.1 biallelic minimally deleted region flanking translocations breakpoints at both derivative chromosome 1 homologues. The deletion resulted in the downregulation of the Fc receptor-like family genes FCRL1, FCRL2, and FCRL3 and in the lack of expression of FCRL5, observed by RT-qPCR. The mutational status of TP53, NOTCH1, SF3B1, MYD88, FBXW7, and XPO1 was investigated by targeted next-generation sequencing, detecting a frameshift deletion within NOTCH1 (c.7544_7545delCT). We hypothesize a loss of tumor suppressor function for FCRL genes, cooperating with NOTCH1 mutation and 13q14 genomic loss in our patient, both conferring a negative prognosis, independently from the known biological prognostic factors of CLL.

Entities:  

Keywords:  1q23.1 deletion; CLL; FCRL; IGHV; NOTCH1; Translocation

Mesh:

Substances:

Year:  2019        PMID: 30877410     DOI: 10.1007/s10238-019-00551-0

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  4 in total

1.  Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma.

Authors:  Yu Liu; Yiding Chen; Xianyu Hu; Jialin Meng; Xiaojing Li
Journal:  Biomed Res Int       Date:  2020-08-22       Impact factor: 3.411

2.  HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  J Transl Med       Date:  2021-01-23       Impact factor: 5.531

3.  Survival correlation of immune response in human cancers.

Authors:  Yuexin Liu
Journal:  Oncotarget       Date:  2019-12-03

4.  A role for the immune system in advanced laryngeal cancer.

Authors:  Marta Tagliabue; Fausto Maffini; Caterina Fumagalli; Sara Gandini; Daniela Lepanto; Federica Corso; Salvatore Cacciola; Alberto Ranghiero; Alessandra Rappa; Davide Vacirca; Maria Cossu Rocca; Daniela Alterio; Elena Guerini Rocco; Augusto Cattaneo; Francesco Chu; Stefano Zorzi; Giuseppe Curigliano; Susanna Chiocca; Massimo Barberis; Giuseppe Viale; Mohssen Ansarin
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.